ResMed Inc. (RMD) Earnings Call Transcripts
ResMed Inc.'s Latest Earnings Call - September 15, 2026
In the fiscal Q1 2027 earnings call for ResMed Inc. (RMD:US), management reported a strong revenue growth outlook, guiding for 5% to 7% growth despite a $75 million headwind from the Astral recall. Revenue growth was driven by a robust demand for sleep devices, with a notable 8% growth in the Americas. The company also indicated a commitment to double-digit EPS growth, signaling operational efficiency. Management emphasized the potential tailwind from GLP-1 prescriptions, which have shown higher adherence rates among patients using CPAP therapy, suggesting a positive impact on future revenues.
Reported metrics
| Metric | Value |
|---|---|
| Revenue Growth | 8% (beat) |
| EPS Growth Guidance | 12% to 14% (inline) |
| Total Addressable Market | 2.7 billion people (positive) |
| Impact from GLP-1s | 11% higher start rate (positive) |
| Gross Margin Improvement | low double-digit basis points (neutral) |
| Astral Recall Charge | $42 million (negative) |
Guidance from management
Management maintained revenue growth guidance of 5% to 7% for fiscal 2027, with expectations for double-digit EPS growth, indicating confidence in operational execution and market demand.
What management said
I think it's both. I think it's definitely more acute right now just given the supply constraints that exist. But I also just think again, with more and more of the demand going to the AI companies, I definitely think that we are going to have a smaller purchasing power. And it's again, why? We're so focused on our productivity pipeline, driving margin expansion, making sure that we're driving cost savings initiative...
Spot on. So when you think about our productivity pipeline, it builds quarter on quarter-on-quarter. The inflationary impact that we have, and we saw it exiting Q4 and we saw a slight sequential decline quarter-over-quarter Q3 to Q4 in our margins, as an example, as a result of that. And so that's one. And then two, pricing, we just started to implement price increases here in Q1. And so there's almost no impact on...
What analysts pressed on
Analysts expressed concerns regarding the impact of the Astral recall on future revenues and the competitive landscape with Philips reentering the market. There were also questions about the sustainability of growth driven by GLP-1 prescriptions and the effectiveness of patient engagement initiatives.
Main topics on the call
- Revenue Growth Guidance — Management provided guidance for the first time, indicating a revenue growth of 5% to 7%, which translates to 6.3% to 8.3% when excluding the $75 million impact from the Astral recall. "Our goal is to meet or beat that m...
- Impact of GLP-1 Prescriptions — Management highlighted that patients with both CPAP and GLP-1 prescriptions show an 11% higher start rate for therapy compared to a control group. This trend suggests that GLP-1s could provide a 50 to 125 basis point boo...
- Acquisitions and Market Expansion — ResMed acquired Noctrix for restless leg syndrome, expanding its market reach to 400 million people worldwide. This acquisition is expected to generate approximately $20 million in revenue, enhancing ResMed's portfolio.
- Cost Pressures and Margin Management — Management acknowledged inflationary pressures on gross margins due to rising costs in freight and electromechanical components. However, they expect low double-digit basis point improvements in gross margins annually th...
Read the full ResMed Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ResMed Inc.
ResMed Inc. (RMD) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 72 calls on record spanning January 13, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 72 ResMed Inc. earnings call transcripts on record, spanning January 13, 2020 to September 15, 2026. Based on this history, ResMed Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RMD
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Calls on record
- 72
- First call
- January 13, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly